NCT00542425View on ClinicalTrials.gov

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

PHASE2CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Osteoporosis
Interventions
DRUG

teriparatide

teriparatide 20 µg subcutaneous daily

DRUG

Placebo

Placebo subcutaneous daily

DRUG

BA058 20 µg

BA058 20 µg subcutaneous daily

DRUG

BA058 40 µg

BA058 40 µg subcutaneous daily

DRUG

BA058 80 µg

BA058 80 µg subcutaneous daily

Trial Locations (1)

02139

Radius Health, Inc., Cambridge

All Listed Sponsors
lead

Radius Health, Inc.

INDUSTRY

NCT00542425 - Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis | Biotech Hunter | Biotech Hunter